Completed PHASE1 INTERVENTIONAL 5-arm NCT03286218

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

A Randomized, Subject- and Investigator-Blind, Placebo and Active-Controlled Study to Assess the Abuse Potential of Lasmiditan

Sponsor: Eli Lilly and Company

Conditions Prescription Drug Abuse (Not Dependent) Recreational Drug Use

Interventions Alprazolam Lasmiditan Placebo

Updated 7 times since 2017 Last updated: Dec 20, 2019 Started: Sep 15, 2017 Primary completion: Nov 20, 2017 Completion: Nov 20, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Prescription Drug Abuse (Not Dependent) and Recreational Drug Use and is currently completed. Eli Lilly and Company leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Feb 2020 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Oct 2017 — Dec 2017 [monthly]

Recruiting PHASE1

First recorded

Sep 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Overland Park, United States